GSK in £1.2bn deal for sleeping pill rights
Tuesday 15 July 2008
The UK's biggest pharmaceutical group, GlaxoSmithKline, is to pay up to £1.2bn for the rights to develop and sell almorexant, an anti-insomnia treatment in its final stage of testing.
GSK will initially spend £66m to help the drug's Swiss maker, Actelion, push the sleeping pill through its phase three trials in Europe. Assuming almorexant passes the licencing requirements, Glaxo's will be liable to pay additional sums relating to sales and other applications for the treatment.
A spokesperson for the group said yesterday the deal was unlikely to result in the whole £1.2bn being paid and declined to comment on what other trials were likely for almorexant.
According to analysts at Dresdner Kleinwort, almorexant is expected to be ready for market by 2011. With 80 million sufferers in the United States alone, experts at JP Morgan Cazenove argue that the US market for insomnia treatments is worth up to $1.2bn.
GSK and Actelion have agreed to continue to pool research into insomnia treatments, although at present this does not extend beyond almorexant.
Analysts covering GSK had one eye on the group's interim results, due next week. It will be one of the first chances the group's chief executive, Andrew Witty, has had to talk directly to shareholders who have seen the stock fall steadily over the past 12 months.
Jeremy Batstone-Carr, an analyst at Charles Stanley, reckons that Mr Witty will take the opportunity to outline his strategy, two months into the job.
- 1 Rules on 5p plastic bags likely to lead to arguments at the check-out
- 2 Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
- 3 Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
- 4 News agency criticised for describing Amal Clooney as 'actor's wife' in coverage of human rights trial
- 5 David De Gea to Real Madrid: Real finally get their man with £29m bid for Manchester United goalkeeper
Rules on 5p plastic bags likely to lead to arguments at the check-out
Watch the Supermoon live: How to see the brightest Moon of the year tonight
Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Turkey duped the US, and Isis reaps rewards
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Theresa May says migrants should be banned from entering the UK unless they have jobs lined up
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...